Close Menu
Search
Reinventing Medicine
Redefining Treatment Paradigms
About Us
Our Company
Leadership
Kymera Cares
Science & Innovation
Our Approach
Pipeline
Resource Library
Careers & Culture
Working at Kymera
Open Positions
Patients
Media
Investors
Patients
Media
Investors
Reinventing Medicine
Redefining Treatment Paradigms
About Us
Our Company
Leadership
Kymera Cares
Science & Innovation
Our Approach
Pipeline
Resource Library
Careers & Culture
Working at Kymera
Open Positions
Search
Back to All Resources
Mechanisms of Anti-Tumor Activity of STAT3 Degraders in Lymphoma
December 7, 2020
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
View Presentation
Area of Focus
Oncology
Programs
STAT3 (KT-333)
Indications
Liquid Tumors
Development Stage
Pre-clinical Data
Share
You may also be interested in these resources
June 14, 2023
Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors
International Conference on Malignant Lymphoma (ICML) 2023
CTCL
LGL-L
PTCL
Solid Tumors
View Resource
October 19, 2022
KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo
20th Annual Discovery on Target Conference
Liquid Tumors
Solid Tumors
View Resource
June 1, 2022
Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CTCL
LGL-L
PTCL
Solid Tumors
View Resource